Editorial Board
(Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - November 26, 2017 Category: Psychiatry & Psychology Source Type: research
ECNP Calendar of Events
(Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - November 26, 2017 Category: Psychiatry & Psychology Source Type: research
Contents
(Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - November 26, 2017 Category: Psychiatry & Psychology Source Type: research
Anterior cingulate volume predicts response to psychotherapy and functional connectivity with the inferior parietal cortex in major depressive disorder
In major depressive disorder (MDD), the anterior cingulate cortex (ACC) has been associated with clinical outcome as well as with antidepressant treatment response. Nonetheless, the association between individual differences in ACC structure and function and the response to cognitive behavioral therapy (CBT) is still unexplored. For this aim, twenty-five unmedicated patients with MDD were scanned with structural and resting state functional magnetic resonance imaging before the beginning of CBT treatment. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - November 24, 2017 Category: Psychiatry & Psychology Authors: Fabio Sambataro, Nadja Doerig, J ürgen Hänggi, Robert Christian Wolf, Janis Brakowski, Martin Grosse Holtforth, Erich Seifritz, Simona Spinelli Source Type: research
RBFOX1, encoding a splicing regulator, is a candidate gene for aggressive behavior
The RBFOX1 gene (or A2BP1) encodes a splicing factor important for neuronal development that has been related to autism spectrum disorder and other neurodevelopmental phenotypes. Evidence from complementary sources suggests that this gene contributes to aggressive behavior. Suggestive associations with RBFOX1 have been identified in genome-wide association studies (GWAS) of anger, conduct disorder, and aggressive behavior. Nominal association signals in RBFOX1 were also found in an epigenome-wide association study (EWAS) of aggressive behavior. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - November 23, 2017 Category: Psychiatry & Psychology Authors: No èlia Fernàndez-Castillo, Gabriela Gan, Marjolein M.J. van Donkelaar, Mariliis Vaht, Heike Weber, Wolfgang Retz, Andreas Meyer-Lindenberg, Barbara Franke, Jaanus Harro, Andreas Reif, Stephen V. Faraone, Bru Cormand Source Type: research
Fluoxetine, not donepezil, reverses anhedonia, cognitive dysfunctions and hippocampal proteome changes during repeated social defeat exposure
While anhedonia is considered a core symptom of major depressive disorder (MDD), less attention has been paid to cognitive dysfunctions. We evaluated the behavioural and molecular effects of a selective serotonin re-uptake inhibitor (SSRI, fluoxetine) and an acetylcholinesterase inhibitor (AChEI, donepezil) on emotional-cognitive endophenotypes of depression and the hippocampal proteome. A chronic social defeat (SD) procedure was followed up by “reminder” sessions of direct and indirect SD. Anhedonia-related behaviour was assessed longitudinally by intracranial self-stimulation (ICSS). (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - November 23, 2017 Category: Psychiatry & Psychology Authors: M.G. Gottschalk, P. Mortas, M. Haman, S. Ozcan, B. Biemans, S. Bahn Source Type: research
A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study)
Based on many clinical and preclinical findings the ‘vigilance regulation model of mania’ postulates that an unstable regulation of wakefulness is a pathogenetic factor in both mania and Attention Deficit Hyperactivity Disorder (ADHD) and induces hyperactivity and sensation seeking as an autoregulatory attempt to stabilize wakefulness. Accordingl y, stimulant medications with their vigilance stabilizing properties could have rapid antimanic effects similar to their beneficial effects in ADHD. The MEMAP study – a multi-center, double-blind, placebo-controlled and randomized clinical trial (RCT) – assessed the antima...
Source: European Neuropsychopharmacology - November 23, 2017 Category: Psychiatry & Psychology Authors: Ulrich Hegerl, Roland Mergl, Christian Sander, Jens Dietzel, Istvan Bitter, Koen Demyttenaere, Ricardo Gusm ão, Ana Gonzalez-Pinto Arrillaga, Iñaki Zorrilla, Adriana García Alocén, Victor Perez Sola, Eduard Vieta, Georg Juckel, Ulrich S. Zimmermann, M Source Type: research
Divergent prefrontal dopaminergic mechanisms mediate drug- and fear-associated cue extinction during adolescence versus adulthood
Cue-associated learning is vital to guiding behaviour for survival. Adolescence represents a key developmental stage for perturbations in cue-related learning, including a characteristic deficit in cue extinction learning. The present review summarizes evidence from animal and human literature that cue extinction is critically mediated by prefrontal dopamine, a system that undergoes dramatic reorganization during adolescence. We propose that extinction learning and memory is governed by a developmentally dynamic balance of dopamine receptors in the prefrontal cortex, which changes across adolescence into adulthood. (Source...
Source: European Neuropsychopharmacology - November 23, 2017 Category: Psychiatry & Psychology Authors: Isabel C. Zbukvic, Jee Hyun Kim Tags: REVIEW Source Type: research
RBFOX1, encoding a splicing regulator, is a candidate gene for aggressive behavior
The RBFOX1 gene (or A2BP1) encodes a splicing factor important for neuronal development that has been related to autism spectrum disorder and other neurodevelopmental phenotypes. Evidence from complementary sources suggests that this gene contributes to aggressive behavior. Suggestive associations with RBFOX1 have been identified in genome-wide association studies (GWAS) of anger, conduct disorder, and aggressive behavior. Nominal association signals in RBFOX1 were also found in an epigenome-wide association study (EWAS) of aggressive behavior. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - November 23, 2017 Category: Psychiatry & Psychology Authors: No èlia Fernàndez-Castillo, Gabriela Gan, Marjolein M.J. van Donkelaar, Mariliis Vaht, Heike Weber, Wolfgang Retz, Andreas Meyer-Lindenberg, Barbara Franke, Jaanus Harro, Andreas Reif, Stephen V. Faraone, Bru Cormand Source Type: research
Impaired repair of DNA damage is associated with autistic-like traits in rats prenatally exposed to valproic acid
Prenatal exposure to the antiepileptic and mood stabilizer valproic acid (VPA) is an environmental risk factor for autism spectrum disorders (ASD), although recent epidemiological studies show that the public awareness of this association is still limited. Based on the clinical findings, prenatal VPA exposure in rodents is a widely used preclinical model of ASD. However, there is limited information about the precise biochemical mechanisms underlying the link between ASD and VPA. Here, we tested the effects of increasing doses of VPA on behavioral features resembling core and secondary symptoms of ASD in rats. (Source: Eur...
Source: European Neuropsychopharmacology - November 23, 2017 Category: Psychiatry & Psychology Authors: Michela Servadio, Antonia Manduca, Francesca Melancia, Loris Leboffe, Sara Schiavi, Patrizia Campolongo, Maura Palmery, Paolo Ascenzi, Alessandra di Masi, Viviana Trezza Source Type: research
Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies
Major depressive disorder (MDD) is a severe psychiatric syndrome with high prevalence and socioeconomic impact. Current antidepressant treatments are based on the blockade of serotonin (5-hydroxytryptamine, 5-HT) and/or noradrenaline transporters. These drugs show slow onset of clinical action and limited efficacy, partly due to the activation of physiological negative feed-back mechanisms operating through autoreceptors (5-HT1A, 5-HT1B, α2-adrenoceptors) and postsynaptic receptors (e.g., 5-HT3). (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - November 22, 2017 Category: Psychiatry & Psychology Authors: Francesc Artigas, Analia Bortolozzi, Pau Celada Tags: REVIEW Source Type: research
Increased cortical neuronal responses to NMDA and improved attentional set-shifting performance in rats following prebiotic (B-GOS ®) ingestion
We have previously shown that prebiotics (dietary fibres that augment the growth of indigenous beneficial gut bacteria) such as Bimuno ™ galacto-oligosaccharides (B-GOS®), increased N-methyl-D-aspartate (NMDA) receptor levels in the rat brain. The current investigation examined the functional correlates of these changes in B-GOS®-fed rats by measuring cortical neuronal responses to NMDA using in vivo NMDA micro-iontophoresis el ectrophysiology, and performance in the attentional set-shifting task. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - November 22, 2017 Category: Psychiatry & Psychology Authors: Benjamin Gronier, Helene M. Savignac, Mathieu Di Miceli, Sherif M. Idriss, George Tzortzis, Daniel Anthony, Philip W.J. Burnet Source Type: research
Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials
Azapirones, which are serotonin1A (5-HT1A) receptor partial agonists, have been used as an adjunctive treatment for schizophrenia with mixed results. This is a meta-analysis of the efficacy and tolerability of azapirones for schizophrenia based on randomized, double-blind, placebo-controlled trials (RCTs). English and Chinese databases were systematically and independently searched by two investigators. Data were extracted and analyzed using the RevMan software (version 5.3). Seven RCTs (n = 368) of azapirones (buspirone in 6 RCTs and tandospirone in 1 RCT) were identified and analyzed. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - November 22, 2017 Category: Psychiatry & Psychology Authors: Wei Zheng, Xiao-Hong Li, Dong-Bin Cai, Xin-Hu Yang, Gabor S. Ungvari, Chee H. Ng, Yu-Ping Ning, Yu-Tao Xiang Source Type: research
Adolescent environmental enrichment prevents the emergence of schizophrenia-like abnormalities in a neurodevelopmental model of schizophrenia
In the present study, we investigated whether exposure to an enriched environment (EE) during adolescence might affect the behavioural dysfunction (sensorimotor gating deficit, memory and social interaction impairments) and neurochemical changes (GAD67 expression, histone methylation) induced by methylazoxymethanol (MAM) in the MAM-E17 rat model of schizophrenia. EE was introduced for 7 days in early adolescence (days 23 –29), and behavioural and biochemical studies were performed on adult rats at postnatal day 70. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - November 22, 2017 Category: Psychiatry & Psychology Authors: Ewelina Bator, Joachim Latusz, Krzysztof W ędzony, Marzena Maćkowiak Source Type: research
